Sep 2025 (Q3 FY25) — Nov 6, 2025
AstraZeneca Q3 FY25 — Broad-based growth powers unprecedented catalyst run toward $80B 2030 ambition
Read the full callAstraZeneca (AZN) earnings
- Sep 2025 (Q3 FY25)
- Dec 2025
AstraZeneca earnings: last reported Thu, 6 Nov 2025, for the quarter ended Sep 2025.
Price
$163.95 −0.88% · −$1.46
Performance −4.1% 1Y
1Y: $170.88 on 17 Oct 2025 → $163.95. High $209.48 (17 Feb 2026), low $155.62 (4 Aug 2026).
- Previous close
- $165.41
- 52-week range
- $155.62 – $209.48
- One year
- −1.81%
Overview
- Symbol
- AZN
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
AstraZeneca earnings calls (AZN)
Financials
What the filings say
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total liabilities | 46,607 | 46,781 | 51,091 | 66,076 | 59,425 | 61,953 | 63,164 | 65,355 |
| Fixed assets | 7,421 | 7,688 | 8,251 | 9,183 | 8,507 | 9,402 | 10,252 | 12,962 |
| Total assets | 60,651 | 61,377 | 66,729 | 105,363 | 96,483 | 101,119 | 104,035 | 114,074 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 2,618 | 2,969 | 4,799 | 5,963 | 9,808 | 10,345 | 11,861 | 14,575 |
| Cash from investing | 963 | -657 | -285 | -11,058 | -2,960 | -4,064 | -7,980 | -6,808 |
| Cash from financing | -2,044 | -1,765 | -2,203 | 3,649 | -6,823 | -6,567 | -3,996 | -7,544 |
| Capital expenditure | -1,043 | -979 | -961 | -1,091 | -1,091 | -1,361 | -1,924 | -2,810 |
| Free cash flow | 1,575 | 1,990 | 3,838 | 4,872 | 8,717 | 8,984 | 9,937 | 11,765 |
Insider filings
9 filings between Apr 7, 2026 and Oct 6, 2026.
Open market
decisions to buy or sellPurchases
$3.2K
1 purchase by 1 insider
Sales
$2.21M
1 sale by 1 insider
Compensation
not trading decisions- 7
- Award — granted as compensation
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Sharma Mani | $3.2K | $2.21M | Aug 8, 2026 |
Latest filings (9)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 6, 2026 | Sharma Mani See remarks | Award | 2 | $320 |
| Sep 8, 2026 | Sharma Mani See Remarks | Award | 1 | $163 |
| Aug 8, 2026 | Sharma Mani See Remarks | Purchase | 20 | $3.2K |
| Aug 6, 2026 | Sharma Mani SVP, Group Controller | Award | 2 | $327 |
| Jul 6, 2026 | Sharma Mani See Remarks | Award | 2 | $381 |
| Jun 8, 2026 | Sharma Mani See Remarks | Award | 1 | $180 |
| May 20, 2026 | Sharma Mani See Remarks | Sale | 11,893 | $2.21M |
| May 6, 2026 | Sharma Mani See Remarks | Award | 1 | $186 |
| Apr 7, 2026 | Sharma Mani See Remarks | Award | 1 | $196 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for ASTRAZENECA PLC
Free account. Everything above stays public.
Write why you follow ASTRAZENECA PLC and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading